Trial Profile

Phase 2 study of CRN04894 in Cushing-syndrome

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atumelnant (Primary)
Indications Cushing syndrome
Focus Therapeutic Use

Most Recent Events

04 May 2023 According to a Crinetics Pharmaceuticals media release, data from this study is expected in 2024.
09 Jan 2023 According to a Crinetics Pharmaceuticals media release, the company plans to conduct this study in the first quarter of 2023.
25 May 2022 According to a Crinetics Pharmaceuticals media release, Patient Studies of CRN-04894 in Cushing's Disease and Congenital Adrenal Hyperplasia to Initiate Later this Year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com